
Jean-Marc Naccache

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2833232/publications.pdf Version: 2024-02-01



IEAN-MARC NACCACHE

#	Article	IF	CITATIONS
1	Acute Exacerbation of Idiopathic Pulmonary Fibrosis: Outcome and Prognostic Factors. Respiration, 2012, 83, 28-35.	1.2	127
2	Lung cancer and interstitial lung disease: a literature review. Journal of Thoracic Disease, 2018, 10, 3829-3844.	0.6	126
3	Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer. European Respiratory Review, 2019, 28, 190058.	3.0	73
4	Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respiratory Medicine,the, 2022, 10, 26-34.	5.2	62
5	Lung Cancer in Combined Pulmonary Fibrosis and Emphysema: A Series of 47 Western Patients. Journal of Thoracic Oncology, 2014, 9, 1162-1170.	0.5	61
6	Study protocol: exploring the efficacy of cyclophosphamide added to corticosteroids for treating acute exacerbation of idiopathic pulmonary fibrosis; a randomized double-blind, placebo-controlled, multi-center phase III trial (EXAFIP). BMC Pulmonary Medicine, 2019, 19, 75.	0.8	20
7	Lung function in Birt-Hogg-Dubé syndrome: a retrospective analysis of 96 patients. Orphanet Journal of Rare Diseases, 2020, 15, 120.	1.2	15
8	Interstitial Lung Disease Associated with Lung Cancer: A Case–Control Study. Journal of Clinical Medicine, 2020, 9, 700.	1.0	14
9	Computed tomography assessment of peripheral traction bronchiolectasis: impact of minimal intensity projection. European Respiratory Journal, 2020, 55, 1901388.	3.1	3
10	Diffuse cystic lung disease in sickle cell anaemia: a series of 22 cases and a case–control study. Thorax, 2022, 77, 91-93.	2.7	3
11	Authors' reply. Lancet Respiratory Medicine,the, 2022, 10, e4.	5.2	Ο